Increased Toxicity When PD-(L)1 Inhibitor Is Followed by Osimertinib

The treatment landscape for advanced non-small cell lung cancer (NSCLC) is constantly changing. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is standard of care for EGFR-mutant NSCLC, and the indications for PD-(L)1 targeting immune checkpoint inhibitors are rapidly expanding and include metastatic (first-line and beyond) and locally advanced disease. With the introduction of multiple novel […]

Read More

Pertuzumab and Trastuzumab Combo Active For HER2-Positive mCRC

For patients with HER2-overexpressed or -amplified breast or gastric cancer, treatment with HER2-targeting agents is standard of care.  HER2 amplification/overexpression in metastatic colorectal cancer (mCRC) is rare (approximately 2% to 6% of patients). This low frequency of HER2 alterations has constrained investigations of HER2-targeted therapies in mCRC. However, based on the activity of HER2-targeted combinations […]

Read More

Immune Checkpoint Inhibitors in Patients With NSCLC and Brain Metastases

Immune checkpoint inhibitors (ICI) targeting PD-1 and PD-L1 are a standard treatment for metastatic non-small cell lung cancer (NSCLC) across multiple lines of therapy for patients who do not possess targetable driver mutations. While as many as 40% of patients with advanced NSCLC will develop brain metastases during the course of their disease, patients with […]

Read More

No Value for Lymphadenectomy in Advanced Ovarian Cancer

Most patients with ovarian cancer are diagnosed in an advanced stage. The standard of care for these patients is maximal cytoreductive surgical debulking, followed by systemic treatment including platinum-based chemotherapy and targeted therapies (eg, bevacizumab, olaparib maintenance in patients harboring BRCA mutations). The goal of primary surgical cytoreduction is removal of as much of the […]

Read More

New Androgen Receptor Inhibitor for Nonmetastatic Prostate Cancer

Delaying the development of metastases is a major goal in the management of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), as these patients typically have poor outcomes and short survival once their disease becomes metastatic. Currently, two androgen receptor (AR) inhibitors apalutamide and enzalutamide are approved for patients with nmCRPC, based on results of the […]

Read More

Four Oncology Indications Approved by FDA in January and February

Subcutaneous Trastuzumab Now Available in US for HER2- Positive Breast Cancer. The FDA approved trastuzumab and hyaluronidase-oysk injection (Herceptin Hylecta™, Genentech), a subcutaneous (SC) formulation of trastuzumab, for treatment of patients with HER2-positive breast cancer. Approval was based on results from the HannaH and SafeHER studies, which compared trastuzumab and hyaluronidase-oysk to standard intravenous (IV) […]

Read More

PI3K Inhibitor Duvelisib Is an Option for Refractory Indolent NHL

Indolent non-Hodgkin lymphoma (iNHL) is a chronic, incurable disease in which patients often require multiple lines of therapy. iNHL include several subtypes including follicular lymphoma (FL), small lymphocytic lymphoma (SLL), and marginal zone B-cell lymphoma (MZL). While chemotherapy and anti-CD20 antibodies are the standards of care in early lines of treatment, there are limited options […]

Read More

Immunotherapy Plus Targeted Therapy, a New Strategy for Advanced RCC

For years, the standard of care for previously untreated patients with advanced renal cell carcinoma (RCC) was single-agent treatment with a vascular endothelial growth factor recepto(VEGFR)-targeting tyrosine kinase inhibitors (TKIs), most commonly sunitinib. However, in the past year, combination immunotherapy with the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab showed improved survival compared to […]

Read More

Immunotherapy Safe and Effective for Cancer Patients With HIV Infection

Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, and CTLA-4 have become key treatments for many advanced cancers due to their ability to induce durable responses and prolong survival. Patients with human immunodeficiency virus (HIV) infection are at increased risk of developing cancer, such as lung cancer, head and neck cancer, anal cancer, and Hodgkin lymphoma, […]

Read More

Stereotactic Radiation Improves Survival in Inoperable Stage I NSCLC

Patients with stage I non-small cell lung cancer (NSCLC), who are not eligible for surgical resection, can still potentially be cured with radiotherapy alone. Advances in radiotherapy technology have led to the development of stereotactic ablative body radiotherapy (SABR), a technique that enables very precise delivery of high-radiation (ablative) doses to small tumors in a […]

Read More